- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Histamine Receptor.
Displaying page 1 of 1.
EudraCT Number: 2010-019344-39 | Sponsor Protocol Number: BUCUM1 | Start Date*: 2010-08-09 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound:... | ||
Medical condition: Cold contact urticaria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001199-39 | Sponsor Protocol Number: MulticenterEbastineIBS | Start Date*: 2013-11-21 |
Sponsor Name:KULeuven | ||
Full Title: Histamine 1 receptor antagonist ebastine as novel treatment in IBS | ||
Medical condition: Patients who suffer from irritable bowel syndrome which are diarrhea predominant and mixed (alteration of constipation and diarrhea) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002512-89 | Sponsor Protocol Number: ANDA1 | Start Date*: 2012-01-26 | |||||||||||
Sponsor Name:Tayside Clinical Trials Unit, University of Dundee | |||||||||||||
Full Title: Evaluation of any steroid sparing effect of beta blocker therapy on airway hyper-responsiveness in stable, mild to moderate, asthmatics. | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001840-38 | Sponsor Protocol Number: BET207 | Start Date*: 2008-08-05 | |||||||||||
Sponsor Name:OBEcure | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects | |||||||||||||
Medical condition: obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003879-42 | Sponsor Protocol Number: 2021/ABM/03/00006 | Start Date*: 2023-04-12 | ||||||||||||||||
Sponsor Name:Medical Univeristy of Bialystok | ||||||||||||||||||
Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility | ||||||||||||||||||
Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001879-73 | Sponsor Protocol Number: E3810-A001-202 | Start Date*: 2016-06-27 |
Sponsor Name:Eisai Medical Research Inc. | ||
Full Title: Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients | ||
Medical condition: Gastroesophageal Reflux Disease | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-006726-26 | Sponsor Protocol Number: 101266 | Start Date*: 2007-03-05 |
Sponsor Name:Orexo AB | ||
Full Title: An open-label randomised observer-blind study to evaluate 24-hour intragastric pH profile at day 1 and day 14 during treatment with a fixed combination of a histamine type 2 receptor antagonist and... | ||
Medical condition: Frequent heartburn | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002154-36 | Sponsor Protocol Number: CIGE025F1301 | Start Date*: 2019-02-13 | ||||||||||||||||
Sponsor Name:Novartis Pharma KK | ||||||||||||||||||
Full Title: A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled... | ||||||||||||||||||
Medical condition: Severe Japanese cedar pollinosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005084-32 | Sponsor Protocol Number: D6230C00001 | Start Date*: 2015-06-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002555-10 | Sponsor Protocol Number: ORCA2015 | Start Date*: 2015-11-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Imperial College | ||||||||||||||||||||||||||||||||||||||
Full Title: Effect of the CRTH2 antagonist OC459 on the response to rhinovirus challenge in asthma | ||||||||||||||||||||||||||||||||||||||
Medical condition: Asthma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002242-36 | Sponsor Protocol Number: GB001-2001 | Start Date*: 2018-12-06 | |||||||||||
Sponsor Name:GB001, Inc. | |||||||||||||
Full Title: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to sev... | |||||||||||||
Medical condition: Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001251-40 | Sponsor Protocol Number: MEA115588 | Start Date*: 2012-10-16 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon... | ||
Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-004117-33 | Sponsor Protocol Number: H3B109689 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D Ltd | |||||||||||||
Full Title: A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selec... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001883-39 | Sponsor Protocol Number: P02561 | Start Date*: 2004-09-21 | |||||||||||
Sponsor Name:Schering Plough Reserach Institute | |||||||||||||
Full Title: Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Ha... | |||||||||||||
Medical condition: Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014415-12 | Sponsor Protocol Number: MEA112997 | Start Date*: 2010-01-04 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled ref... | |||||||||||||
Medical condition: severe uncontrolled refractory asthma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005615-21 | Sponsor Protocol Number: 205.341 | Start Date*: 2006-07-13 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Ti... | |||||||||||||
Medical condition: Patients with severe persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002828-37 | Sponsor Protocol Number: D2912C00003 | Start Date*: 2021-09-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose ranging, Multi centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder Twice Daily for Fou... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000460-42 | Sponsor Protocol Number: AK001-002 | Start Date*: 2016-06-29 | |||||||||||
Sponsor Name:Allakos, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis | |||||||||||||
Medical condition: Moderate to severe nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Completed) NL (Prematurely Ended) DE (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001413-14 | Sponsor Protocol Number: 205.416 | Start Date*: 2008-08-20 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ... | |||||||||||||
Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001414-25 | Sponsor Protocol Number: 205.417 | Start Date*: 2008-08-20 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ... | |||||||||||||
Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.